NextCure closed at $5.85 on Nov 4, down 1.02%, 59.0% below its 52-week closing high. Volume of 39.4K shares was 0.57× its 20-day average (below normal).
Split-adjusted performance: +2.9% over one month, -45.4% over six months, -51.2% over one year.
Short interest was 221.0K shares at the Oct 15 settlement, up 3.6% from the prior report (8.4% of float, 3.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NXTCNextCure | $5.85 | −1.02% | −45.4% | — | — | — | $26.8M | |
| ABVCABVC BioPharma | $1.00 | +1.51% | −9.1% | — | — | — | $26.7M | Compare |
| RNAZTransCode Therapeutics | $1.60 | +1.91% | −78.7% | — | — | — | $27.1M | Compare |
| CELUCelularity | $0.8088 | −1.02% | −13.0% | −5.3% | 10.1% | — | $26.2M | Compare |
| AARDAardvark Therapeutics | $1.26 | +2.44% | −78.6% | — | — | — | $27.6M | Compare |
| FLNAFilana Therapeutics | $0.5720 | −3.75% | — | — | — | — | $27.6M | Compare |
| BCTXBriacell Therapeutics | $3.19 | +5.98% | −23.1% | — | — | — | $27.9M | Compare |
| BYSIBeyondSpring | $0.6790 | +9.34% | −56.2% | — | — | — | $27.9M | Compare |
| CPHIChina Pharma Holdings | $0.5875 | −3.56% | +11.4% | −7.5% | −153.8% | — | $25.3M | Compare |
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
